Our basic and clinical research has contributed to the development of pharmaceuticals that has included pivotal treatments for ocular herpes, corneal ulcers, and dry eyes. Read More
Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles May 24, 2013 - The new agreement was negotiated through Blue Mountain Technologies, a program of Mount Sinai Innovation Partners.
Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration May 22, 2013 - Partnership will accelerate the pace of discovery and innovation in Biomedical Sciences.
Ketamine Shows Significant Benefit in People with Treatment-Resistant Depression May 20, 2013 - Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic.
